Next-generation sequencing broad panel assays. A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to identify actionable targets.

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE. GUILDFORD, SURREY/ ACCESSWIRE/ September 23, 2024/ ANGLE plc, a world-leading liquid biopsy company with innovative ...

OGT, A Sysmex Group Company, announces the recent launch of several new solutions to support its growing NGS portfolio. These include the SureSeq™ Myeloid Plus panel, which has been designed to detect ...

Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical ...

--QIAGEN today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis, the world’ s leading infectious disease ...

Under the agreement, QIAGEN will design and validate a multimodal panel using its NGS technology on the Illumina NextSeq 550Dx platform. This diagnostic tool will identify genomic alterations in ...

The agreement grants Angle the exclusive global use (outside of China) of NuProbe’s NGS panel which the company claims can detect more than 6,500 DNA mutations in 61 clinically relevant genes.

Purpose To evaluate the cost effectiveness of next-generation sequencing (NGS) panels for the diagnosis of colorectal cancer and polyposis (CRCP) syndromes in patients referred to cancer genetics ...

GUILDFORD, SURREY / ACCESSWIRE / September 23, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).